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doi:10.1016/j.jtcvs.2004.02.038Objective: The purpose of this study was to evaluate the feasibility of using
autologous sheep marrow stromal cells cultured onto polyglycolic acid mesh to
develop helical engineered cartilage equivalents for a functional tracheal replace-
ment. We also explored the potential benefit of local delivery of transforming
growth factor 2 with biodegradable gelatin microspheres.
Methods: Bone marrow was obtained by iliac crest aspiration from 6-month-old
sheep and cultured in monolayer for 2 weeks. At confluence, the cells were seeded
onto nonwoven polyglycolic acid fiber mesh and cultured in vitro with transforming
growth factor 2 and insulin-like growth factor 1 for 1 week. Cell-polymer con-
structs were wrapped around a silicone helical template. Constructs were then
coated with microspheres incorporating 0.5 g transforming growth factor 2. The
cell-polymer-microsphere structures were then implanted into a nude rat. On re-
moval, glycosaminoglycan content and hydroxyproline were analyzed in both native
and tissue-engineered trachea. Histologic sections of both native and tissue-engi-
neered trachea were stained with hematoxylin and eosin, safranin-O, and a mono-
clonal anti–type II collagen antibody.
Results: Cell-polymer constructs with transforming growth factor 2 microspheres
formed stiff cartilage de novo in the shape of a helix after 6 weeks. Control
constructs lacking transforming growth factor 2 microspheres appeared to be much
stiffer than typical cartilage, with an apparently mineralized matrix. Tissue-engi-
neered trachea was similar to normal trachea. Histologic data showed the presence
of mature cartilage. Glycosaminoglycan and hydroxyproline contents were also
similar to native cartilage levels.
Conclusions: This study demonstrates the feasibility of engineering tracheas with
sheep marrow stromal cells as a cell source. Engineering the tracheal equivalents
with supplemental transforming growth factor 2 seemed to have a positive effect
on retaining a cartilaginous phenotype in the newly forming tissue.
At present it is still not known which cartilage source is the easiestto obtain and which requires the least invasive techniques forharvesting to provide a cellular sample for constructing a tissue-engineered trachea (TET). We have observed and published thatnasal septum cartilage is a potential site for obtaining an adequatesample for further tissue engineering studies.1,2 What is advanta-
geous about hyaline cartilage of the nasal septum is that not only is it very similar
to tracheal cartilage but it is also a source for epithelial cells and connective tissues.
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septum biopsy specimen one is able to culture out three
different cell types, each necessary for in vitro 3-dimen-
sional tissue construction. However, cartilage harvested
from nasal tissue should not be considered a universal
source for all cases where tissue engineering could be
beneficial, for example in patients with smoke inhalation
and in children.
Other cellular sources that have the potential use in
tissue-engineering studies need to be investigated. Recently
it has been demonstrated that stem cells may be a potential
source that can be exploited by tissue engineers.3 For engi-
neering bone and cartilage, our laboratory believes that
marrow stromal cells (MSCs) hold the greatest therapeutic
potential. An additional advantage of using stromal stem
cells is that obtaining them is less invasive than removing a
sample of nasal cartilage.
This study was designed to evaluate the feasibility of
using autologous sheep MSCs cultured onto a polyglycolic
acid (PGA) mesh to develop a helically engineered cartilage
equivalent of a functional trachea. Transforming growth
factor (TGF)  has been shown to play a major role in
cartilage development, and studies have demonstrated that
TGF-2 helps support chondrogenesis in developing 3-di-
mensional tissue constructs. We therefore explored the po-
tential benefits of local delivery of TGF-2 to cells with
biodegradable microspheres. We were able to locally de-
liver TGF-2 by coupling its release to the degradation of a
biodegradable hydrogel prepared by cross-linking acidic
gelatin with glutaraldehyde. This gelatin hydrogel incorpo-
rating TGF-2 effectively promoted cartilage regeneration
in vivo.
Materials and Methods
Preparation of Gelatin Microspheres Incorporating
TGF-2
Gelatin with an isoelectric point of 5.0, prepared through alkaline
Figure 1. Phase-contrast photomicrograph at 200 of
colonizing surface of culture flask at 4 days. B, Cells
became confluent.procedure of bovine bone, was kindly supplied from Nitta Gelatin
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isoelectric point. Gelatin microspheres were prepared by chemical
cross-linking of gelatin in a water-in-oil emulsion state, as de-
scribed previously.4 Briefly, aqueous solution of 10% by weight
gelatin (10 mL) was preheated at 40°C and then added dropwise
into 375 mL olive oil preheated at 40°C, while an impeller stirring
at 420 rpm was performed for 10 minutes to yield a water-in-oil
emulsion. The emulsion temperature was decreased to 4°C, fol-
lowed by further stirring for 30 minutes for the natural gelation of
gelatin aqueous solution. Cold acetone (100 mL) was added to the
emulsion, and stirring was continued for 10 minutes. The resulting
microspheres were washed three times with cold acetone, collected
by centrifugation (5000 rpm, 4°C, 5 minutes), fractionated in size
by sieves with apertures of 70 and 100 m, and air-dried at 4°C.
The average diameter of the microspheres used was 75 m. The
non–cross-linked and dried gelatin microspheres (20 mg) were
placed in 20 mL of 0.1% by weight polysorbate 80 aqueous
solution containing 100 L of 25% by weight glutaraldehyde
solution and stirred at 4°C for 24 hours to allow the gelatin to
cross-link. After washing by centrifugation (5000 rpm, 4°C, 5
minutes) with double-distilled water, the microspheres were agi-
tated in 20 mL of 100-mmol/L aqueous glycine solution at room
temperature for 1 hour to block the residual aldehyde groups of
unreacted glutaraldehyde. The resulting microspheres were
washed three times with double-distilled water by centrifugation
and freeze-dried. To impregnate TGF-2 into gelatin micro-
spheres, 20 L of 100-mmol/L phosphate-buffered saline solution
(pH 7.4) containing 20 g TGF-2 was dropped onto 2 mg of the
freeze-dried gelatin microspheres and left overnight at 4°C. The
TGF-2 was completely incorporated into gelatin microspheres by
this impregnation procedure because the volume of TGF-2 solu-
tion was small enough compared with that theoretically incorpo-
rated into the microspheres.
Cell Isolation and Culture
Sheep bone marrow cells were obtained by iliac crest aspiration
from 6 month-old sheep. The aspirate were cultured in Dulbecco
modified Eagle medium (GIBCO; Life Technologies, Inc, Rock-
ville, Md) containing 10% fetal calf serum (GIBCO; Life Tech-
nologies) with 292-g/mL L-glutamine, 10,000-U/mL penicillin
p MSCs in monolayer culture. A, Cells attaching and
tinued to proliferate, and after 14 days initial cultureshee
conG, 10,000-U/mL streptomycin sulfate, and 25 g/mL amphotericin
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2 weeks, a confluent monolayer was obtained (Figure 1, B). Cells
were harvested by digestion with 0.05% trypsin–ethylenediami-
netetraacetic acid (GIBCO; Life Technologies). The isolated cells
were counted with a hemocytometer, and their viability was de-
termined with use of the trypan-blue (Sigma-Aldrich, Irvine, Calif)
exclusion method.
Cell Seeding and Implantation
Cell suspensions were concentrated at 50  106 cells/mL and
seeded on a 100  10  2-mm nonwoven mesh of PGA fibers
(Davis & Geck, Danbury, Conn; Figure 2, A). The serum-contain-
ing media was then replaced with Dulbecco modified Eagle me-
dium with ITSPremix (Becton Dickinson Microbiology Sys-
tems, Sparks, Md), L-ascorbic acid 2-phosphate (Sigma, St Louis,
Mo), 10-nmol/L dexamethasone, TGF-2 (10 ng/mL) (PeproTech,
Inc, Rocky Hill, NJ), and insulin-like growth factor 1 (25 ng/mL)
(PeproTech). The cell-seeded mesh samples were continuously
cultured for 1 week in vitro (Figure 2, B and C). Please note the
initial cell seeding number needs to be at least 50  106 cells/mL,
because when we change the medium every day unattached cells
spill out of the PGA mesh and are lost. This is the why we seed the
PGA mesh at such a high concentration. The structures were then
placed in the grooves of a 20-mm diameter  50-mm long helical
template made with a Silastic ERTV mold-making kit (Dow Corn-
ing, Midland, Mich). Cell-polymer samples were coated with
gelatin microspheres with (n  6) or without (n  6) TGF-2
(Figure 3, A). The composite structures were implanted subcuta-
neously in athymic rats and harvested after 6 weeks (Figure 3, B).
Figure 2. A, Cells attaching to PGA on day 0. B, Growth
cells firmly attached to PGA by day 4.The implants were analyzed histologically and biochemically.
The Journal of ThoraciTissue was assayed for cartilage-specific extracellular matrix com-
ponents, including proteoglycans and collagen. All animals re-
ceived humane care in compliance with the “Principles of Labo-
ratory Animals Care” formulated by the National Society for
Medical Research and the “Guide for the Care and Use of Labo-
ratory Animals” (http://www.nap.edu/catalog/5140.html). All ani-
mal procedures complied with the guidelines provided by the
institutional animal care and use committee of the University of
Massachusetts Medical School.
Histologic Examinations
The specimens for histology were fixed in 10% phosphate-buff-
ered formalin and embedded in paraffin and sectioned. Sections
were stained with hematoxylin, eosin, safranin-O and a mouse
monoclonal anti–type II collagen antibody.
Biochemical Analysis
Samples were digested by the addition of 1.0 mL of 100-mmol/L
sodium phosphate, 10-mmol/L sodium ethylenediaminetetraacetic
acid, and 10-mmol/L cysteine hydrochloride (Sigma). The speci-
mens were incubated in the 60°C water bath for 24 hours.5
Glycosaminoglycan content. The glycosaminoglycan content
of tissue digested was quantified according to a previously de-
scribed method.6 Briefly, 50 L papain digest was added to 2 mL
1,9-dimethylmethylene blue dye at pH 3.0, with absorbencies
detected at 490 nm with a spectrophotometer immediately after the
addition of the dye. Glycosaminoglycan contents of the specimens
were determined with chondroitin 6-sulfate from shark cartilage
(Sigma) as a standard. All samples and standards were analyzed in
lls and matrix on day 7. C, Electron microscopy showsof ceduplicate.
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for the hydroxyproline quantification7. Briefly, the papain digests
were hydrolyzed with equal volumes of 6N hydrochloric acid at
115°C for 16 to 24 hours in screw cap glass tubes. Contents of each
tube were washed out and transferred into a borosilicate 12 
75-mm glass tube and dried for 5 hours. Chloramine T hydrate
(98%; Sigma) and p-dimethylaminobenzaldehyde (Ehrlich re-
agent; Sigma) were added to hydrolyzed specimens, and absor-
bencies were detected at 560 nm with a spectrophotometer imme-
diately after the addition of the dye. Collagen content in
experimental samples were determined with hydroxyproline stan-
dard from Sigma.
Results
The tissue appearance of specimens prepared with gelatin
microspheres without TGF-2 showed fibrous remnants of
Figure 4. TET from nude rat at 6 weeks after implantation.
Figure 3. A, Cell-seeded matrix was placed in grooves
kit. B, Constructs coated with gelatin microspheres
pockets on nude rats.PGA. However, the tissue appearance of specimens pre-
150 The Journal of Thoracic and Cardiovascular Surgery ● Julypared with gelatin microspheres incorporating TGF-2 in-
cluded neovascularization on the surface of engineered car-
tilage and what appeared to be cartilage.
Gross Morphology
The gross appearance of the TET was solid and shiny white
with a cartilaginous circular helix. The TET showed great
similarity native trachea. In addition, these TETs were stiff
to the touch yet flexible, similar to native cartilage (Figure
4).
Histology
On histologic examination, the engineered surface was
found to be smooth, and formation of cartilage was evident.
Hematoxylin and eosin and safranin-O stains demonstrated
hyaline cartilage closely resembling that of native tracheal
cartilage with similar overall morphologic characteristics
(Figure 5, A-D). Staining for type II collagen was strongly
positive in both native and engineered cartilage (Figure 5, E
and F).
Biochemical Assay
Six samples of TET and native trachea were analyzed for
proteoglycan and collagen contents. Proteoglycan content
of the TET was 49.57  6.81 g/mg, and that in the native
tracheal cartilage was 63.05  7.3 g/mg. Proteoglycan
content of the TET was similar to that in native trachea
(Figure 6, A). The collagen content of the TET was 0.35 
0.37 g/mg, and that in native tracheal cartilage was 0.49
2.43 g/mg. The collagen content of the TET was similar to
that in native trachea (Figure 6, B). There were no statisti-
cally significant differences in glycosaminoglycan and hy-
droxyproline when native and engineered samples were
compared (P  .50).
Discussion
This study shows the feasibility of engineering trachea in
elical templates fabricated with silicone mold-making
rporating TGF-2 were implanted into subcutaneousof h
incovitro with sheep MSCs as a cell source. In addition to simple
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Harvesting bone marrow under local anesthesia obviates the
risk and expense associated with general anesthesia. For
critically injured patients, a major population that may need
tracheal replacement surgery, this is particularly advanta-
geous. Because of MSCs’ unique ability to form at least five
types of connective tissues, including bone and cartilage8, it
is possible to create cartilage with a less invasive aspiration
technique. In combination with in vitro tissue culturing, it is
possible to obtain large numbers of each of the cell types,
further sparing the patient from multiple procedures.
For this study, MSCs were allowed to reach confluence,
in approximately 2 weeks, before they were treated with any
growth factors that would result in the differentiation of the
MSCs into connective tissues. The growth factors TGF-1,
TGF-2, and TGF-3 have the ability to induce chondro-
genic differentiation in chondrocyte and mesenchymal stem
cells; however, not with equal effect. Barry and colleagues9
have reported that TGF-2 and TGF-3 promote chondro-
genesis more potently than does TGF-1, causing a 2-fold
greater accumulation of glycosaminoglycan and a more
extensive deposition of type II collagen than if cells are
Figure 5. Hematoxylin and eosin staining (magnifica
staining was deeply positive, indicative of abundant p
(D). Staining for type collagen II was strongly positiv
native (F) sections.treated with TGF-1. Therefore after 2 weeks the cells were
The Journal of Thoraciseeded onto a PGA mesh and cultured with TGF-2 and
insulin-like growth factor 1 for an additional week to induce
differentiation. The cells were also cultured with insulin-
like growth factor 1 because it helps to regulate cellular
proliferation as well as increasing extra cellular matrix
synthesis and metabolism, processes crucial for cartilage
regulation.
In gross morphologic appearance, the TET was very
similar to native tracheal cartilage in that it had excellent
rigidity and patency. We observed significant angiogene-
sis on the surface of engineered cartilage, providing the
necessary vascular supply needed by the new tissue.
Cartilage differentiation was dependent on TGF-2, as
demonstrated by the fact that the samples treated with
biodegradable, gelatin microspheres lacking TGF-2
group did not differentiate into cartilage effectively.
However, microspheres containing TGF-2 released
through an extended period induced significant chondro-
genic differentiation. This is in agreement with previ-
ously published reports demonstrating that TGF- is in
part responsible for the formation of fibrous scar tissue.10
Although we saw extensive angiogenesis and tissue for-
100) of TET (A) and native trachea (B). Safranin-O
glycan production, in both TET (C) and native trachea
extensive extracellular matrix of engineered (E) andtion
roteo
e inmation, we could not definitively state that the tissue
c and Cardiovascular Surgery ● Volume 128, Number 1 151
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sheep tissue. However, we feel confident that the tissue
between the rings was rat tissue because sheep MSCs
were seeded into circular grooves of the template only,
not spread across the entire surface of the template.
Clinical treatment strategies in the future would use the
patient’s own cells, thus eliminating any potential immu-
nologic reactions. For this reason we did not feel it was
necessary to differentiate rat tissue from sheep tissue in
this study. We conclude that the controlled release of
TGF-2 not only enhanced chondrogenesis but also in-
duced connective tissue growth, resulting in neovascu-
larization.
A histologic evaluation of the TET 6 weeks after
implantation revealed mature hyaline cartilage with
evenly distributed lacunae that contained single chondro-
cytes. Safranin-O staining was deeply positive, indicative
of abundant proteoglycan production in the matrix. There
was evidence of chondrogenic differentiation, demon-
strated by the positive staining for type II collagen in the
extracellular matrix of the engineered cartilage. Bio-
chemical analysis comparing the proteoglycan and colla-
gen contents in TET and native tracheal cartilage dem-
Figure 6. A, Glycosaminoglycan (GAG) contents of native trachea
and TET. B, Hydroxyproline contents of native trachea and TET.
Bar heights represent mean of 6 observations; error bars repre-
sent SD. Data were not statistically different according to 1-way
analysis of variance.onstrated that the proteoglycan content of the TET was
152 The Journal of Thoracic and Cardiovascular Surgery ● July49.57  6.81 g/mg, approximately 78% of that of
native tracheal cartilage (63.05  7.3 g/mg). The col-
lagen content of the TET was 0.35  0.37 g/mg, 71%
of that of native tracheal cartilage (0.49  2.43 g/mg).
These results clearly demonstrate that TET derived from
MSCs is similar to native tissue, and we are optimistic
about the potential for generating human trachea in vivo
by culturing sheep MSCs onto PGA fibers and using
biodegradable microspheres to deliver locally TGF-2.
We thank Gregory Hendricks for performing the scanning
electron microscopy. We also thank Michelle Maynard for her
expert technical assistance and preparation of materials for these
experiments.
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Discussion
Dr Paolo Macchiarini (Hannover, Germany). Tracheal trans-
plantation has been the subject of ongoing research for more than
40 years, without success. The concept of TET is the most recent,
and maybe the “sexiest,” idea that has been generated in recent
years. However, there are a few points that everybody should
know to understand the process and rationale behind tracheal
transplantation. I advise a look at the review by Grillo in The
Annals of Thoracic Surgery (2002;73:1995-2004) a few months
ago. I saw him yesterday. “You know why I did this review on
tracheal transplantation,” he said simply. “Well, I would like that
the youngest that are doing this research have a look, so that the
killing of small and large animals should be stopped.”
There are a few concerns and a few questions. My concern is,
could you, for instance, isolate the given cells only from the
peripheral blood and not from a bone marrow biopsy sample? I ask
2004
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patient with cancer.
Dr Kojima. I agree. I would not suggest this tissue-engineering
technique in a patient with cancer. I would use it for benign
polychondritis or some other injury.
Dr Macchiarini. The second question is, I saw in your slides
a tube just made from cartilage and nothing else. I understand that
the trachea is an organ with its own vascular pedicle, its own
function. This is not only the contracted function but an immuno-
logic and a mechanical function. How do you deal with ischemia
if one segment is longer than 6 cm, which is what we really need
in clinical practice?
Dr Kojima. I agree, vascularization is the most important
factor. So when we move to autologous model, which means we
harvest sheep MSCs and then implant them into the same sheep
under the sternocleidomastoid muscle, maybe we will want to use
The Journal of Thoraciboth TFG-2 and fibroblast growth factor, because TGF-2 both
induces cartilaginous differentiation and forms fibrous tissue. Fi-
broblast growth factor also induces vascularization. And we have
data demonstrating that both TGF-2 and fibroblast growth factor
can be released from the gelatin microspheres. Also, for cartilage
to grow it may be necessary to have perichondrium present to
provide nutrients to the growing cartilage. So it might be necessary
to consider how to differentiate perichondrium from other MSCs.
I believe that we will be able to make a functional trachea, but I am
not sure about longer than 6 cm.
With respect to epithelialization, we think that if we use less than
5 cm of TET, which is 8 to 10 tracheal rings, we don’t need epithe-
lialization. We have data demonstrating that epithelialization can be
grown and expanded from both native sides. Even if epithelialization
cannot grow, it doesn’t matter, because with less than a 5-cm defect,
the sheep can skip this lesion with a light cough.
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